Else Nutrition

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 828.42
3.94 0.48
556,160
108.42M
US$ 89.820B
US$ 110.64
2.76 2.56
1.21M
237.77M
US$ 26.310B
US$ 46.83
-3.45 -6.86
13.48M
384.40M
US$ 18.000B
US$ 11.87
0.11 0.94
2.89M
739.52M
US$ 8.780B
US$ 95.42
1.33 1.41
251,055
65.11M
US$ 6.210B
US$ 199.61
14.16 7.64
400,443
28.73M
US$ 5.730B
US$ 103.06
3.90 3.93
836,814
53.76M
US$ 5.540B
US$ 27.09
1.21 4.68
1.70M
188.03M
US$ 5.090B
US$ 54.50
0.00 0.00
337,955
68.21M
US$ 3.720B
US$ 36.38
0.95 2.68
603,723
93.77M
US$ 3.410B
US$ 50.95
1.09 2.19
289,990
64.58M
US$ 3.290B
US$ 48.09
-0.95 -1.94
599,651
54.83M
US$ 2.640B
US$ 81.08
-1.31 -1.59
127,038
30.61M
US$ 2.480B
US$ 59.81
0.03 0.05
654,909
34.29M
US$ 2.050B
US$ 7.10
0.17 2.45
6.56M
275.07M
US$ 1.950B
US$ 16.50
0.36 2.23
592,928
113.31M
US$ 1.870B
US$ 11.03
0.04 0.36
999,221
160.89M
US$ 1.770B
US$ 26.95
1.61 6.35
2.02M
47.98M
US$ 1.290B
US$ 24.96
0.26 1.05
217,277
47.50M
US$ 1.190B
US$ 2.34
0.00 0.00
0
487.70M
US$ 1.140B
US$ 2.88
0.26 9.92
3.65M
333.78M
US$ 961.290M
US$ 2.70
-0.02 -0.74
2.16M
294.67M
US$ 795.610M
US$ 9.24
1.60 20.94
2.91M
84.80M
US$ 783.550M
US$ 15.31
0.00 0.00
0
50.23M
US$ 769.020M
US$ 5.78
0.52 9.89
6.29M
119.35M
US$ 689.840M
US$ 3.01
-0.10 -3.06
1.43M
222.47M
US$ 668.520M
US$ 7.30
0.24 3.40
1.17M
84.44M
US$ 616.410M
US$ 0.50
0.0011 0.22
500,609
1.07B
US$ 536.070M
US$ 6.50
-0.27 -3.99
974,566
75.93M
US$ 493.540M
US$ 4.07
0.04 0.99
836,840
113.56M
US$ 462.190M
US$ 1.27
-0.03 -2.31
2.93M
361.49M
US$ 459.090M
US$ 6.70
0.16 2.45
1.95M
68.08M
US$ 456.140M
US$ 2.28
0.17 8.06
8.88M
196.22M
US$ 447.380M
US$ 6.03
0.00 0.00
0
68.39M
US$ 412.390M
US$ 0.30
0.04 15.42
1.86M
1.25B
US$ 375.120M
US$ 8.49
0.11 1.31
542,344
43.10M
US$ 365.920M
US$ 5.83
0.04 0.69
159,113
56.62M
US$ 330.090M
US$ 8.18
0.00 0.00
657,622
36.21M
US$ 296.200M
US$ 2.00
0.07 3.63
903,246
126.05M
US$ 252.100M
US$ 18.78
0.26 1.40
260,683
12.04M
US$ 226.110M
US$ 3.19
-0.08 -2.45
792,614
70.56M
US$ 225.090M
US$ 2.76
0.26 10.40
7.07M
78.89M
US$ 217.740M
US$ 10.81
2.47 29.62
348,645
18.65M
US$ 201.610M
US$ 2.64
0.19 7.76
1.00M
71.34M
US$ 188.340M
US$ 3.00
0.16 5.63
239,209
62.28M
US$ 186.840M
US$ 3.18
0.00 0.00
0
58.24M
US$ 185.200M
US$ 5.71
0.27 4.96
149,117
30.34M
US$ 173.240M
US$ 5.01
-0.62 -11.01
179,463
32.59M
US$ 163.280M
US$ 1.99
-0.08 -3.86
626,272
69.88M
US$ 139.060M
US$ 1.89
0.08 4.42
8,200
70.18M
US$ 132.640M
US$ 4.91
0.00 0.00
0
25.13M
US$ 123.390M
US$ 0.12
-0.0017 -1.40
9.26M
997.95M
US$ 119.750M
US$ 2.64
-0.44 -14.29
161,726
44.27M
US$ 116.870M
US$ 2.72
0.00 0.00
0
42.81M
US$ 116.440M
US$ 0.97
-0.04 -3.50
264,852
119.44M
US$ 115.260M
US$ 8.16
-0.45 -5.23
276,785
13.05M
US$ 106.490M
US$ 1.91
-0.03 -1.55
148,744
49.78M
US$ 95.080M
US$ 2.54
-0.10 -3.79
64,651
36.47M
US$ 92.630M
US$ 6.92
-0.33 -4.55
195,188
13.01M
US$ 90.030M
US$ 1.76
0.07 4.14
139,104
48.26M
US$ 84.940M
US$ 1.70
0.16 10.39
522,498
43.28M
US$ 73.580M
US$ 22.93
0.00 0.00
0
3.13M
US$ 71.770M
US$ 2.41
-0.10 -3.98
630,570
29.29M
US$ 70.590M
US$ 0.96
0.12 14.85
768,351
68.40M
US$ 65.530M
US$ 1.82
0.00 0.00
0
33.43M
US$ 60.840M
US$ 1.09
-0.03 -2.68
219,547
55.16M
US$ 60.120M
US$ 0.38
0.00 0.00
0
150.86M
US$ 57.930M
US$ 22.80
-0.50 -2.15
18,342
2.50M
US$ 57.000M
US$ 2.22
-0.02 -0.67
155,912
25.54M
US$ 56.570M
US$ 1.90
-0.03 -1.55
235,010
29.65M
US$ 56.340M
US$ 2.13
0.03 1.19
123,558
24.61M
US$ 52.300M
US$ 1.86
0.11 6.29
167,421
27.45M
US$ 51.060M
US$ 2.77
0.35 14.46
81,509
17.64M
US$ 48.860M
US$ 1.85
0.01 0.54
11,546
26.30M
US$ 48.660M
US$ 12.01
0.00 0.00
0
4.05M
US$ 48.640M
US$ 1.63
0.16 10.88
8,941
25.93M
US$ 42.270M
US$ 1.00
0.01 1.01
86,269
41.49M
US$ 41.490M
US$ 2.36
0.04 1.72
210,245
15.81M
US$ 37.310M
US$ 1.51
-0.07 -4.43
28,500
24.53M
US$ 37.040M
US$ 3.76
0.07 1.90
60,374
9.66M
US$ 36.320M
US$ 0.42
0.00 0.00
0
86.00M
US$ 36.160M
US$ 13.93
0.00 0.00
0
2.43M
US$ 33.850M
US$ 1.14
0.05 4.59
13,282
29.48M
US$ 33.610M
US$ 1.21
0.00 0.00
0
27.58M
US$ 33.370M
US$ 1.07
0.05 4.91
18,458
29.89M
US$ 31.990M
US$ 1.00
0.00 0.00
0
30.11M
US$ 30.110M
US$ 2.20
0.00 0.00
277,622
12.88M
US$ 28.340M
US$ 1.14
0.08 7.17
66,683
23.99M
US$ 27.350M
US$ 0.65
-0.50 -43.56
116,061
38.26M
US$ 24.830M
US$ 4.56
0.03 0.66
17,515
5.39M
US$ 24.560M
US$ 2.91
0.00 0.00
2,987
8.32M
US$ 24.210M
US$ 0.70
-0.01 -1.95
716,246
30.71M
US$ 21.340M
US$ 1.47
-0.01 -0.68
29,015
14.36M
US$ 21.110M
US$ 0.46
0.00 0.00
0
45.54M
US$ 20.920M
US$ 2.91
0.00 0.00
0
6.98M
US$ 20.310M
US$ 11.80
10.00 555.56
1,035
1.61M
US$ 19.000M
US$ 1.37
0.05 3.79
69,516
13.49M
US$ 18.480M
US$ 0.05
0.00 0.00
0
369.39M
US$ 18.470M
US$ 0.45
0.00 0.00
0
40.60M
US$ 18.270M
US$ 0.34
0.01 3.93
302,811
46.79M
US$ 16.080M
US$ 0.41
0.00 0.00
0
36.03M
US$ 14.900M
US$ 0.14
-0.0002 -0.14
6.52M
103.12M
US$ 14.540M
US$ 0.56
0.02 2.94
183,912
25.15M
US$ 13.980M
US$ 0.44
0.00 0.00
337,127
27.92M
US$ 12.280M
US$ 0.22
0.00 0.00
0
55.37M
US$ 11.930M
US$ 1.29
0.00 0.00
0
9.24M
US$ 11.920M
US$ 0.12
0.00 0.00
0
98.66M
US$ 11.650M
US$ 0.03
-0.0005 -1.72
135,000
406.27M
US$ 11.580M
US$ 0.80
-0.02 -2.63
273,977
14.40M
US$ 11.520M
US$ 2.61
0.11 4.40
341,488
4.19M
US$ 10.940M
US$ 0.16
0.00 0.00
0
69.64M
US$ 10.930M
US$ 3.53
-0.04 -1.21
13,272
2.97M
US$ 10.470M
US$ 8.05
-0.11 -1.35
8,871
1.28M
US$ 10.300M
US$ 1.64
-0.18 -9.65
68,018
5.97M
US$ 9.790M
US$ 2.12
-0.08 -3.64
18,422
4.58M
US$ 9.710M
US$ 0.02
-0.0033 -13.31
1,900
443.14M
US$ 9.530M
US$ 0.06
0.00 0.00
0
172.20M
US$ 9.490M
US$ 0.39
-0.03 -7.53
2.43M
24.08M
US$ 9.470M
US$ 0.26
0.007 2.82
1.45M
36.39M
US$ 9.280M
US$ 7.09
-0.17 -2.34
11,841
1.25M
US$ 8.860M
US$ 2.01
-0.05 -2.43
92,968
4.34M
US$ 8.720M
US$ 1.43
0.00 0.00
0
5.85M
US$ 8.380M
US$ 0.20
-0.006 -2.90
106,261
39.72M
US$ 7.980M
US$ 2.42
-0.16 -6.20
20,100
3.25M
US$ 7.860M
US$ 0.45
-0.02 -3.28
219,375
17.27M
US$ 7.850M
US$ 0.06
0.00 0.00
0
123.53M
US$ 7.470M
US$ 0.73
0.03 4.93
8.18M
8.82M
US$ 6.440M
US$ 0.05
0.00 0.00
0
139.47M
US$ 6.280M
US$ 1.54
0.14 10.00
498,741
3.98M
US$ 6.130M
US$ 4.75
0.00 0.00
0
1.26M
US$ 5.980M
US$ 0.08
0.00 0.00
0
74.56M
US$ 5.980M
US$ 0.25
0.0042 1.69
404,395
23.65M
US$ 5.960M
US$ 1.10
0.02 1.71
5,404
5.41M
US$ 5.940M
US$ 3.76
-0.18 -4.57
13,158
1.54M
US$ 5.790M
US$ 0.24
0.00 0.00
0
23.90M
US$ 5.760M
US$ 1.85
0.00 0.00
0
2.99M
US$ 5.530M
US$ 0.06
0.00 0.00
0
96.42M
US$ 5.420M
US$ 2.81
-0.35 -11.08
71,497
1.75M
US$ 4.920M
US$ 4.59
-0.38 -7.65
36,910
1.05M
US$ 4.820M
US$ 1.99
-0.17 -7.87
251,559
2.27M
US$ 4.520M
US$ 1.54
0.09 6.56
14,751
2.90M
US$ 4.470M
US$ 0.74
-0.05 -6.33
2
5.97M
US$ 4.420M
US$ 0.16
0.00 0.00
0
27.76M
US$ 4.300M
US$ 0.04
0.00 0.00
0
119.08M
US$ 4.300M
US$ 0.03
0.00 0.00
0
121.27M
US$ 3.520M
US$ 0.32
0.02 6.67
10,000
10.89M
US$ 3.480M
US$ 3.31
-0.33 -9.07
47,380
1.04M
US$ 3.440M
US$ 2.69
-0.03 -1.10
74,331
1.22M
US$ 3.280M
US$ 2.54
-0.0027 -0.11
18,008
1.18M
US$ 2.990M
US$ 1.16
-0.01 -0.85
80,079
2.23M
US$ 2.590M
US$ 0.02
0.00 0.00
43,000
171.56M
US$ 2.570M
US$ 0.23
0.00 0.00
0
10.70M
US$ 2.480M
US$ 8.22
0.00 0.00
0
286,504
US$ 2.360M
US$ 0.03
0.00 0.00
1,170
77.99M
US$ 2.340M
US$ 0.0065
0.0002 3.17
202,100
358.45M
US$ 2.330M
US$ 0.02
0.0045 31.03
4,000
96.36M
US$ 1.830M
US$ 0.03
0.00 0.00
0
47.82M
US$ 1.430M
US$ 0.11
-0.58 -83.86
10,424
12.20M
US$ 1.360M
US$ 0.05
-0.002 -4.17
400
27.30M
US$ 1.260M
US$ 0.0073
0.00 0.00
0
132.63M
US$ 968K
US$ 0.0064
0.00 0.00
0
148.32M
US$ 949K
US$ 0.0054
0.00 0.00
0
116.77M
US$ 631K
US$ 0.25
0.04 19.05
894
1.39M
US$ 348K
US$ 0.008
0.00 0.00
0
35.87M
US$ 287K
US$ 0.09
0.00 0.00
0
708,609
US$ 64K
US$ 0.0001
0.00 0.00
0
79.41M
US$ 8K
US$ 0.0004
0.00 0.00
0
18.98M
US$ 8K
US$ 0.0001
0.00 0.00
0
30.74M
US$ 3K
US$ 0.0002
-0.18 -99.89
7,845
4.70M
US$ 940
US$ 0.00001
0.00 0.00
0
36.50M
US$ 365
US$ 1.71
0.00 0.00
0
-
US$ -

BioTech News


Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial... Read more


BriaCell Therapeutics Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models Novel therapy activates both innate and adaptive immune systems Proof of concept Phase 1/2 Study of Bria-BRES™ in metastatic breast cancer currently underway PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08,... Read more


Humacyte Third Quarter 2024 Financial Results and Business Update

FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing  Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024  Long-term results from the humanitarian program where the ATEV was used to treat vascular... Read more


Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data... Read more


Aequus Pharmaceuticals Provides Update and Reports Third Quarter 2024 Financial Highlights

VANCOUVER – TheNewswire - November 8, 2024 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended September 30, 2024 (“Third Quarter 2024”) and associated Company developments. Unless otherwise... Read more


Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate... Read more


Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities... Read more


Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy...

Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade  Clinical data show benefit of combining immune checkpoint inhibitors in MSS CRC and essential role of CTLA-4 to prime PD-L1 pathway  Clinical poster selected by SITC as a ‘Top 100’ abstract... Read more


Lexaria Bioscience Updates Fast-Moving GLP-1 'Arm's Race' Developments

DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry update. It is no surprise that Novo Nordisk's ("Novo") blockbuster drug, semaglutide,... Read more


Esperion Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth  Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter   October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four... Read more


IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events Company plans to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025... Read more


Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Bi... Read more


AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

VANCOUVER, British Columbia / Nov 07, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera’s presentation, which is available for viewing here, describes: Strategies to address... Read more


Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and MB-101 (IL13Rα2‐targeted CAR-T cell therapy) to optimize clinical results WORCESTER, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”)... Read more


Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108,... Read more


Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities... Read more


ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy LOS ANGELES / Nov 07, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products,... Read more


Xenetic Biosciences Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has... Read more


Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies Enrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple... Read more


Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committe... Read more


Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile -- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached  Preliminary... Read more


Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years LA JOLLA, Calif. / Nov 07, 2024 / Business Wire / Longboard Pharmaceuticals,... Read more


Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN) Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN... Read more


Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024  Advanced Phase 2 LYNX and FOX trials of sevasemten in children and adolescents with Duchenne  Advanced Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM)  Announced positive top-line data from Phase... Read more


Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures... Read more


Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024. "We are very pleased with our performance, highlighted by record third... Read more


Cassava Sciences Reports Q3 2024 Financial and Operating Results

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing... Read more


IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provided an update on its clinical development of IMNN-001 including progress... Read more


PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025  Study designs of CONNECT program optimized based on encouraging results from early cohort  Strengthened leadership team with addition of Paul Streck, MD, MBA, as head of R&D  BOSTON / Nov 07, 2024 / Business Wire / PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology... Read more


HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS